Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00215_DB06414_nanopub.RAPIwa4zvAX_UQUKeqyNWWe2ZMcaoF_fRRfmaChX5IP60#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00215_DB06414 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00215_DB06414 label "DDI between Citalopram and Etravirine - Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration. It is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes). [drugbank_resource:DB00215_DB06414]" assertion.
- drugbank_resource:DB00215_DB06414 identifier "drugbank_resource:DB00215_DB06414" assertion.
- drugbank_resource:DB00215_DB06414 title "DDI between Citalopram and Etravirine - Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration. It is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes)." assertion.
- drugbank:DB00215 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00215_DB06414 assertion.
- drugbank:DB06414 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00215_DB06414 assertion.